Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone

Phase 3 Completed 437 enrolled Sucampo Pharma Americas, LLC Sucampo Pharmaceuticals, Inc. · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary purpose of this study is to evaluate the efficacy and safety of lubiprostone administration in patients with opioid-induced bowel dysfunction (OBD).

Timeline

Start: 2007-08
Primary completion: 2009-03
Completion: 2009-03

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Lubiprostone	Small molecule	24 ug	—

Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone

Summary

Timeline

Drugs

Indications